NCT Number: NCT00093275
HP184 in Chronic Spinal Cord Injury Subjects
The purpose of this study is to determine whether HP184 is effective in the treatment of chronic spinal cord injury (CSCI).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
sanofi-aventis administrative Australia & New-Zealand administrative office, Macquarie Park, New South Wales, Australia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male and female subjects with incomplete (traumatic), chronic (defined as 18 months or more post spinal cord injury) SCI aged 18 to 65 years
- CSCI must be categorized in classes C or D in the ASIA impairment scale. (C = Incomplete impairment with motor function preserved below the neurological level, and more than half of key muscles below the neurological level have a muscle grade less than 3. D = Incomplete impairment with motor function preserved below the neurological level, and at least half of key muscles below the neurological level have a muscle grade more than or equal to 3).
- The level of the SCI must be between C4 and T10 (neurological)
- Subject has a measurable range of motion at the hips, knees and ankles and possesses potential propulsive activity (i.e. no functional contractures)
- Female subjects of childbearing potential (those who are not surgically sterile or who are less than 2 years postmenopausal) must be using two forms of birth control, including a primary and a secondary form and have a negative pregnancy test immediately prior to treatment. Primary forms of contraception include: tubal ligation, partner's vasectomy, intrauterine devices, birth control pills, and topical/injectable/implantable/insertable hormonal birth control products. Secondary forms of contraception include diaphragms, latex condoms and cervical caps; each must be used with a spermicide.
Exclusion criteria
- Any clinical evidence of recent fracture(s) within the last six months prior to study start.
- Any history of Multiple Sclerosis or peripheral demyelinating disease or neuromuscular disorder.
- Heart rate of less than 38 or greater than 100
- Ashworth spasticity score of 0/4 or 4/4 at the hip or knee.
- Subject whose medical condition requires mechanical ventilation.
- Lower motor neuron injury, such as those with conus medullaris or cauda equina injuries.
- Subject with lower extremity amputation or proximal femorectomy.
- Subject with pressure ulcers stages 3 and 4.
- Subject medically or mentally unstable in judgment of Investigator.
- Subject on tricyclic antidepressants such as nortriptyline, amitriptyline and imipramine.
- Subject with ASIA motor score of greater than or equal to 92.
- Subject with ASIA sensory score of greater than or equal to 200.
- Subject with history of seizure within 2 years prior to study start.
- Subjects who have participated in a clinical trial involving investigational medication within 30 days prior to administration of HP184 or placebo.
- Female subjects with positive urine pregnancy test.
- Female subjects who are breast feeding.
Treatment and study plan
Primary outcomes
-
Change from baseline in total motor score of American Spinal Injury Association (ASIA) manual motor test at Week 24.
Secondary outcomes
-
Safety evaluation.
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Sanofi
Industry
Registry information
Official study title
A Phase II, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of HP184 Administered Orally Once Daily for Twenty-Four Weeks in Adult Subjects With Chronic Spinal Cord Injury (CSCI)
Important dates
- Study start
- 2004
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Oct 7, 2004
- Registry last updated
- Aug 21, 2008
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Modified Yoga for Pulmonary Function and Quality of Life in Spinal Cord Injury Patients
NCT07842003
Central Nervous System Diseases, Nervous System Diseases
Ahmedabad, Gujarat, India
View Trial DetailsPNS Motor Stimulation Study
NCT07810712
Brain Diseases, Cardiovascular Diseases
Liverpool, United Kingdom
View Trial DetailsClinical Investigation to Validate the Safety and Performance of Integrating Functional Electrical Stimulation Into the ABLE Exoskeleton
NCT07550699
Acquired Brain Injury (Including Stroke), Autoimmune Diseases
Vienna, State of Vienna, Austria
View Trial DetailsNeuromodulation After Spinal Cord Injury to Improve Limb Function
NCT06815601
Central Nervous System Diseases, Nervous System Diseases
Buffalo, New York, United States
View Trial Details